SGEN - Seattle Genetics Inc Stock Price, Fair Value and News

3711.48USD Market Closed

Market Summary

USD3711.48

Market Closed

SGEN Stock Price

View Fullscreen

SGEN RSI Chart

SGEN Valuation

Market Cap

700.2B

Price/Earnings (Trailing)

-933.34

Price/Sales (Trailing)

304.4

EV/EBITDA

-1.0K

Price/Free Cashflow

-998.58

SGEN Price/Sales (Trailing)

SGEN Profitability

EBT Margin

-32.12%

Return on Equity

-29.42%

Return on Assets

-20.64%

Free Cashflow Yield

-0.1%

SGEN Fundamentals

SGEN Revenue

Revenue (TTM)

2.3B

Rev. Growth (Yr)

27.11%

Rev. Growth (Qtr)

7.42%

SGEN Earnings

Earnings (TTM)

-750.2M

Earnings Growth (Yr)

-13.09%

Earnings Growth (Qtr)

-2.01%

Breaking Down SGEN Revenue

Last 90 days

1522.6%

Trailing 12 Months

1705.6%

How does SGEN drawdown profile look like?

SGEN Financial Health

Current Ratio

2.67

SGEN Investor Care

Shares Dilution (1Y)

1.61%

Diluted EPS (TTM)

-4.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	2.1B	2.2B	2.3B	0
2022	1.7B	1.8B	1.9B	2.0B
2021	2.3B	2.4B	1.7B	1.6B
2020	956.0M	1.0B	1.9B	2.2B
2019	709.3M	757.6M	801.4M	916.7M
2018	513.7M	575.7M	609.8M	654.7M
2017	416.1M	428.9M	457.9M	482.3M
2016	365.8M	384.1M	406.3M	418.1M
2015	300.6M	309.4M	317.7M	336.8M
2014	280.2M	275.0M	279.8M	286.8M
2013	219.9M	244.6M	265.8M	269.3M
2012	130.9M	166.6M	195.8M	210.8M
2011	73.2M	49.4M	54.0M	94.8M
2010	65.8M	79.7M	93.6M	107.5M
2009	0	0	0	52.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Seattle Genetics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 14, 2023	romp charles r	back to issuer	-7,739,280	229	-33,796	evp, commercial u.s.
Dec 14, 2023	welch daniel g	back to issuer	-2,456,020	229	-10,725	-
Dec 14, 2023	love ted w	back to issuer	-974,395	229	-4,255	-
Dec 14, 2023	baker bros. advisors lp	back to issuer	-10,661,600	229	-46,557	-
Dec 14, 2023	liu jean i	back to issuer	-11,163,300	229	-48,748	chief legal officer
Dec 14, 2023	simonian nancy a	back to issuer	-14,370,400	229	-62,753	-
Dec 14, 2023	himes vaughn b	back to issuer	-3,406,150	229	-14,874	chief technical officer
Dec 14, 2023	baker bros. advisors lp	back to issuer	-10,238,200,000	229	-44,708,500	-
Dec 14, 2023	simpson todd e	back to issuer	-21,363,900	229	-93,292	chief financial officer
Dec 14, 2023	welch daniel g	back to issuer	-1,087,750	229	-4,750	-

Which funds bought or sold SGEN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 29, 2024	Kapitalo Investimentos Ltda	sold off	-100	-14,984,200	-	-%
Mar 22, 2024	PNC Financial Services Group, Inc.	sold off	-100	-1,684,680	-	-%
Mar 21, 2024	HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	sold off	-100	-39,523,500	-	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-2,826,060,000	-	-%
Mar 06, 2024	SageView Advisory Group, LLC	sold off	-100	-262,218	-	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-75,104,300	-	-%
Mar 01, 2024	READYSTATE ASSET MANAGEMENT LP	sold off	-100	-26,216,200	-	-%
Mar 01, 2024	ROYAL LONDON ASSET MANAGEMENT LTD	sold off	-100	-11,598,400	-	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	sold off	-100	-3,229,980	-	-%
Feb 21, 2024	Garde Capital, Inc.	sold off	-100	-309,000	-	-%

Are Funds Buying or Selling SGEN?

Are funds buying SGEN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SGEN

No. of Funds

Unveiling Seattle Genetics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Dec 18, 2023	baker bros. advisors lp	0.0%	0	SC 13D/A
Jun 09, 2023	capital international investors	3.9%	7,227,865	SC 13G/A
May 03, 2023	baker bros. advisors lp	23.8%	44,617,299	SC 13D/A
Mar 13, 2023	baker bros. advisors lp	25.1%	46,985,656	SC 13D/A
Feb 13, 2023	capital international investors	9.7%	18,058,081	SC 13G/A
Feb 09, 2023	vanguard group inc	6.97%	12,945,078	SC 13G/A
Feb 06, 2023	wellington management group llp	5.32%	9,881,292	SC 13G/A
Feb 01, 2023	blackrock inc.	6.4%	11,861,464	SC 13G/A
Mar 10, 2022	baker bros. advisors lp	25.6%	46,975,613	SC 13D/A
Feb 11, 2022	capital international investors	7.0%	12,778,429	SC 13G/A

Peers (Alternatives to Seattle Genetics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	0.01%	-33.89%	-8.42	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.06%	-27.57%	-42.25	10.17	76.23%	61.08%
BMRN	17.3B	2.4B	9.12%	-7.56%	103	7.14	15.42%	18.43%
INCY	12.0B	3.7B	-8.48%	-28.30%	20.07	3.25	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-9.27%	-36.41%	-11.74	15.65	425.83%	18.94%
BBIO	4.5B	-	-6.46%	74.90%	-6.94	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-9.62%	-0.34%	-13.52	11.95	440.80%	-27.84%
ARWR	3.0B	240.7M	-15.06%	-21.14%	-10.03	12.36	-1.03%	-92.09%
ACAD	2.8B	726.4M	-8.60%	-6.11%	-45.41	3.83	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.17%	-12.95%	25.42	4.56	85.90%	-14.05%
NVAX	576.6M	983.7M	-22.12%	-55.02%	-1.06	0.59	-50.36%	17.16%
CRBP	448.6M	881.7K	-2.13%	345.78%	-10.06	466.16	-77.61%	-5.33%
INO	256.8M	4.9M	2.33%	7.75%	-1.9	52.78	-54.97%	51.72%
IBIO	6.7M	2.1M	82.86%	81.13%	-0.25	2.14	-13.45%	66.37%

Seattle Genetics Inc News

Latest updates

Seattle Genetics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	7.4%	648,650,000	603,832,000	519,719,000	528,150,000	510,300,000	497,502,000	426,460,000	429,850,500	424,060,000	388,478,000	331,983,000	601,293,000	1,061,731,000	277,998,000	234,514,000	289,804,000	213,263,000	218,447,000	195,199,000	174,513,000	169,424,000
Costs and Expenses	6.7%	879,988,000	824,553,000	704,232,000	682,154,000	703,105,000	630,613,000	559,510,000	601,920,500	722,023,000	478,081,000	454,403,000	436,307,000	423,545,000	371,963,000	346,869,000	328,218,000	303,047,000	257,157,000	248,836,000	264,824,000	214,998,000
S&GA Expenses	8.9%	265,687,000	243,932,000	236,441,000	216,101,000	210,378,000	220,259,000	174,225,000	210,937,000	180,281,000	165,130,000	159,842,000	158,365,000	127,579,000	125,642,000	122,249,000	115,229,000	96,101,000	82,331,000	80,271,000	79,467,000	57,155,000
R&D Expenses	12.3%	449,047,000	399,868,000	356,015,000	357,843,000	384,605,000	304,254,000	297,659,000	304,293,500	459,092,000	234,861,000	230,426,000	216,183,500	217,670,000	198,077,000	195,199,000	201,061,000	196,119,000	163,929,000	158,265,000	149,772,000	140,175,000
EBITDA Margin	2.3%	-0.30	-0.31	-0.29	-0.28	-0.32	-0.39	-0.39	-0.40	-0.17	0.27	0.29	0.30	-	-	-	-	-	-	-	-	-
Income Taxes	-120.8%	-600,000	2,891,000	4,600,000	4,314,500	2,300,000	107,000	1,300,000	-2,334,000	1,100,000	-	-	-1,211,000	3,200,000	-	-	-	-	-	-	-	-
Earnings Before Taxes	-3.7%	-216,360,000	-208,637,000	-170,113,000	-143,828,000	-188,527,000	-134,720,000	-135,240,000	-176,974,000	-292,735,000	-84,576,000	-121,420,000	165,884,000	639,409,000	-	-	25,830,000	-91,913,000	-	-	-	-
EBT Margin	2.3%	-0.32	-0.33	-0.31	-0.31	-0.34	-0.42	-0.41	-0.43	-0.19	0.25	0.27	0.28	-	-	-	-	-	-	-	-	-
Net Income	-2.0%	-215,789,000	-211,528,000	-174,737,000	-148,171,000	-190,816,000	-134,827,000	-136,494,000	-174,628,000	-293,847,000	-84,576,000	-121,420,000	167,095,000	636,167,000	-21,190,000	-168,402,000	25,830,000	-91,913,000	-79,238,000	-13,329,000	-119,805,000	-67,446,000
Net Income Margin	2.8%	-0.33	-0.34	-0.32	-0.31	-0.34	-0.42	-0.41	-0.43	-0.19	0.25	0.29	0.28	-	-	-	-	-	-	-	-	-
Free Cashflow	64.5%	-79,753,000	-224,475,000	-288,298,000	-108,685,000	-101,663,000	-86,534,000	-234,209,000	-296,958,000	-34,206,000	-87,332,000	-132,841,000	172,634,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	4.0%	3,634	3,495	3,543	3,675	3,619	3,630	3,617	3,720	3,978	3,952	3,943	4,001	3,005	2,165	2,091	2,206	2,098	1,568	1,593	1,503	1,568
Current Assets	1.4%	2,552	2,516	2,602	2,803	2,760	2,779	2,771	2,869	3,115	3,099	3,104	3,062	2,166	1,331	1,160	1,177	1,196	672	680	654	717
Cash Equivalents	38.9%	429	308	336	320	368	375	261	425	685	413	374	558	919	117	249	275	193	64.00	84.00	78.00	115
Inventory	9.1%	531	487	478	427	365	319	276	201	181	163	147	116	97.00	90.00	85.00	86.00	92.00	73.00	67.00	53.00	75.00
Net PPE	16.7%	359	308	264	248	230	219	214	210	209	203	197	197	193	185	175	155	145	131	115	104	101
Goodwill	0%	275	275	275	275	275	275	275	275	275	275	275	275	275	275	275	275	275	275	275	275	251
Current Liabilities	25.1%	955	763	713	818	726	609	531	569	698	434	390	388	593	283	257	259	246	222	208	225	194
Shareholder's Equity	-2.6%	2,550	2,619	2,723	2,804	2,822	2,933	2,998	3,065	3,165	3,391	3,425	3,488	2,258	1,814	1,766	1,876	1,780	1,272	1,313	1,274	1,365
Retained Earnings	-8.5%	-2,756	-2,540	-2,329	-2,154	-2,006	-1,815	-1,680	-1,544	-1,369	-1,075	-990	-869	-1,036	-1,672	-1,651	-1,483	-1,509	-1,417	-1,337	-1,324	-1,204
Additional Paid-In Capital	2.8%	5,302	5,155	5,048	4,954	4,825	4,747	4,678	4,608	4,533	4,466	4,415	4,357	3,294	3,485	3,414	3,359	3,288	2,688	2,651	2,598	2,569
Shares Outstanding	0.5%	189	188	187	187	185	184	184	183	182	181	181	175	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	24,200	-	-	-	21,000	-	-	-	21,100	-	-	-	7,500	-	-	-

Cashflow (Last 12 Months)

(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	79.6%	-35.82	-175	-249	-79.44	-85.73	-71.77	-216	-283	-17.85	-72.44	-125	189	823	-86.28	-69.06	-11.85	-60.65	-34.01	-57.23	-24.28	-11.12
Share Based Compensation	40.9%	131	93.00	64.00	64.00	59.00	54.00	44.00	52.00	45.00	38.00	38.00	40.00	39.00	35.00	34.00	48.00	28.00	26.00	26.00	26.00	21.00
Cashflow From Investing	7.1%	142	133	232	-36.49	65.00	173	27.00	1.00	268	99.00	-78.71	-1,323	-40.33	-76.93	22.00	65.00	-382	3.00	36.00	-16.25	-61.56
Cashflow From Financing	12.4%	16.00	14.00	30.00	65.00	18.00	15.00	27.00	22.00	22.00	13.00	20.00	773	20.00	31.00	22.00	28.00	572	11.00	27.00	3.00	29.00

SGEN Income Statement

2023-09-30

Condensed Consolidated Statements of Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues:
Total revenues	$ 648,650	$ 510,300	$ 1,772,201	$ 1,434,262
Costs and expenses:
Cost of sales	165,254	108,122	457,783	301,848
Research and development	449,047	384,605	1,204,930	986,518
Selling, general and administrative	265,687	210,378	746,060	604,862
Total costs and expenses	879,988	703,105	2,408,773	1,893,228
Loss from operations	(231,338)	(192,805)	(636,572)	(458,966)
Investment and other income, net	14,978	4,278	41,463	479
Loss before income taxes	(216,360)	(188,527)	(595,109)	(458,487)
(Benefit) provision for income taxes	(571)	2,289	6,945	3,650
Net loss	$ (215,789)	$ (190,816)	$ (602,054)	$ (462,137)
Net loss per share - basic (in dollars per share)	$ (1.15)	$ (1.03)	$ (3.21)	$ (2.51)
Net loss per share - diluted (in dollars per share)	$ (1.15)	$ (1.03)	$ (3.21)	$ (2.51)
Shares used in computation of per share amounts - basic (in shares)	188,135	184,792	187,532	184,199
Shares used in computation of per share amounts - diluted (in shares)	188,135	184,792	187,532	184,199
Comprehensive loss:
Net loss	$ (215,789)	$ (190,816)	$ (602,054)	$ (462,137)
Other comprehensive income:
Unrealized gain (loss) on securities available-for-sale, net of tax	97	(875)	1,639	(4,472)
Foreign currency translation gain (loss)	189	3,363	(755)	6,288
Total other comprehensive income	286	2,488	884	1,816
Comprehensive loss	(215,503)	(188,328)	(601,170)	(460,321)
Net product sales
Revenues:
Total revenues	570,729	428,089	1,583,343	1,242,889
Royalty revenues
Revenues:
Total revenues	63,561	43,904	144,927	111,194
Collaboration and license agreement revenues
Revenues:
Total revenues	$ 14,360	$ 38,307	$ 43,931	$ 80,179

SGEN Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 428,568	$ 319,940
Short-term investments	808,418	1,415,130
Accounts receivable, net	631,555	501,912
Inventories	531,188	427,211
Prepaid expenses and other current assets	151,864	138,340
Total current assets	2,551,593	2,802,533
Property and equipment, net	358,801	248,179
Operating lease right-of-use assets	128,861	46,738
Intangible assets, net	220,255	237,516
Goodwill	274,671	274,671
Other non-current assets	100,080	64,895
Total assets	3,634,261	3,674,532
Current liabilities:
Accounts payable	224,813	207,851
Accrued liabilities and other	729,903	610,553
Total current liabilities	954,716	818,404
Long-term liabilities:
Operating lease liabilities, long-term	113,487	43,474
Other long-term liabilities	15,637	8,835
Total long-term liabilities	129,124	52,309
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000 shares authorized; none issued	0	0
Common stock, $0.001 par value, 250,000 shares authorized; 188,628 shares issued and outstanding at September 30, 2023 and 186,559 shares issued and outstanding at December 31, 2022	189	187
Additional paid-in capital	5,302,239	4,954,469
Accumulated other comprehensive income	4,394	3,510
Accumulated deficit	(2,756,401)	(2,154,347)
Total stockholders’ equity	2,550,421	2,803,819
Total liabilities and stockholders’ equity	$ 3,634,261	$ 3,674,532

About Seattle Genetics Inc

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

CEO	Mr. David R. Epstein B.Sc., M.B.A.
WEBSITE	seagen.com
INDUSTRY	Biotechnology
EMPLOYEES	3256

Seattle Genetics Inc Frequently Asked Questions

What is the ticker symbol for Seattle Genetics Inc? What does SGEN stand for in stocks?

SGEN is the stock ticker symbol of Seattle Genetics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Seattle Genetics Inc (SGEN)?

As of Fri Apr 05 2024, market cap of Seattle Genetics Inc is 700.22 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SGEN stock?

You can check SGEN's fair value in chart for subscribers.

What is the fair value of SGEN stock?

You can check SGEN's fair value in chart for subscribers. The fair value of Seattle Genetics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Seattle Genetics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SGEN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Seattle Genetics Inc a good stock to buy?

The fair value guage provides a quick view whether SGEN is over valued or under valued. Whether Seattle Genetics Inc is cheap or expensive depends on the assumptions which impact Seattle Genetics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SGEN.

What is Seattle Genetics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 05 2024, SGEN's PE ratio (Price to Earnings) is -933.34 and Price to Sales (PS) ratio is 304.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SGEN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Seattle Genetics Inc's stock?

In the past 10 years, Seattle Genetics Inc has provided 0.569 (multiply by 100 for percentage) rate of return.